Gene therapy trial hopes to strengthen hearts in rare genetic disease
NCT ID NCT07426419
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This early-stage trial tests a single infusion of AFTX-201, a gene therapy designed to help heart muscle cells produce a missing protein in people with dilated cardiomyopathy caused by a BAG3 gene mutation. About 22 adults with moderate heart failure will be enrolled to check safety and whether the treatment improves heart function. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.